期刊
AMERICAN JOURNAL OF HYPERTENSION
卷 25, 期 6, 页码 644-650出版社
OXFORD UNIV PRESS
DOI: 10.1038/ajh.2012.12
关键词
anti-TNF-alpha; arterial stiffness; blood pressure; carotid intima media thickness; hypertension; rheumatoid arthritis
资金
- Norwegian Foundation for Health and Rehabilitation [2004/2/0255]
- Norwegian Rheumatism Association
- Abbott
- BMS
- MSD/Schering-Plough
- Pfizer/Wyeth
- Roche
- UBS
BACKGROUND Premature arterial stiffening and atherosclerosis are increased in patients with inflammatory arthropathies such as rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA). The proinflammatory protein calprotectin is associated with inflammatory arthropathies, vascular pathology, and acute coronary events. We examined the long-term effects of treatment with tumor necrosis factor (TNF)-alpha antagonists on aortic stiffness and carotid intima media thickness (CIMT) in patients with inflammatory arthropathies, and the relationships to the levels of calprotectin. METHODS Fifty-five patients with RA, AS, or PsA and a clinical indication for anti-TNF-alpha therapy were included and followed with regular examinations for 1 year. Thirty-six patients starting with anti-TNF-alpha therapy were compared with a nontreatment group of 19 patients. Examinations included assessments of aortic stiffness (aortic pulse wave velocity, aPWV), CIMT, and plasma calprotectin. RESULTS After 1 year, aPWV (mean (s.d.)) was improved in the treatment group, but not in the control group (-0.54 [0.79] m/s vs. 0.06 [0.61] m/s, respectively; P = 0.004), and CIMT progression (median (quartile cut-points, 25th and 75th percentiles)) was reduced in the treatment group compared to the control group (-0.002 [-0.038, 0.030] mm vs. 0.030 [0.011, 0.043] mm, respectively; P = 0.01). In multivariable analyses, anti-TNF-alpha therapy over time was associated with improved aPWV (P = 0.02) and reduced CIMT progression (P = 0.04), and calprotectin was longitudinally associated with aPWV (P = 0.02). CONCLUSIONS Long-term anti-TNF-alpha therapy improved aortic stiffness and CIMT progression in patients with inflammatory arthropathies. Calprotectin may be a soluble biomarker reflecting aortic stiffening in these patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据